Physician profile
Michael Eugene Taylor
NPI 1770683203
$3,746.66
in general payments reported to CMS, 2019-2025
35 companies · $453 in 2025
The $453 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $496 · 2020: $85.02 · 2021: $91.75 · 2022: $656 · 2023: $879 · 2024: $1,085 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,417.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $565.60 | 2019-2025 | Qulipta, Dalvance, Teflaro |
| Abbott Laboratories | $427.65 | 2022-2025 | Freestyle Libre 2 |
| Novo Nordisk INC | $365.63 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $213.41 | 2019-2025 | Farxiga, Airsupra |
| Dexcom, INC. | $213.22 | 2021-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $196.29 | 2019-2024 | Repatha, Otezla, Prolia |
| Lilly USA, LLC | $185.94 | 2019-2023 | Mounjaro, Jardiance, Trulicity |
| E.R. Squibb & Sons, L.L.C. | $146.66 | 2019-2024 | Eliquis, Camzyos |
| Mylan Specialty L.P. | $123.88 | 2020-2024 | Yupelri |
| Insulet Corporation | $113.96 | 2023-2024 | Omnipod |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.62 | 2019-2023 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $95.25 | 2024 | Voquezna |
| Astellas Pharma US INC | $94.86 | 2019-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $89.58 | 2019 | |
| Novartis Pharmaceuticals Corporation | $83.19 | 2019-2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $76.65 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.50 | 2019-2024 | Jardiance, Tradjenta |
| Tandem Diabetes Care, INC. | $63.46 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Janssen Biotech, INC. | $61.85 | 2023-2024 | Tremfya |
| Pfizer INC. | $53.19 | 2019-2024 | |
| Averitas Pharma INC. | $51.41 | 2023 | Qutenza |
| Aimmune Therapeutics, INC. | $43.83 | 2025 | Vowst, Zenpep |
| Verona Pharma, INC. | $42.97 | 2025 | Ohtuvayre |
| Glaxosmithkline, LLC. | $40.77 | 2022 | |
| Nestle Healthcare Nutrition INC. | $35.90 | 2021 | |
| Exact Sciences Corporation | $28.76 | 2023 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $28.22 | 2020-2022 | |
| Recor Medical INC | $21.36 | 2025 | Paradise Ultrasound Renal Denervation System |
| Otsuka America Pharmaceutical, INC. | $20.94 | 2024 | Rexulti |
| Sumitomo Pharma America, INC. | $18.96 | 2023 | Gemtesa |
| Rhythm Pharmaceuticals, INC. | $17.74 | 2023 | Imcivree |
| Xeris Pharmaceuticals, INC. | $17.37 | 2025 | Gvoke Hypopen |
| Corcept Therapeutics | $17.29 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $11.31 | 2019 | |
| Kvk-Tech, INC. | $2.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.